China Medical System Holdings Limited (0867.HK)
HKD 7.36
(-0.67%)
HKD 7.36
(-0.67%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 16.67 Million CNY | 23.57% |
| 2022 | 13.49 Million CNY | -97.72% |
| 2021 | 591.62 Million CNY | -0.21% |
| 2020 | 592.88 Million CNY | 5551.33% |
| 2019 | 10.49 Million CNY | -99.27% |
| 2018 | 1.44 Billion CNY | -29.4% |
| 2017 | 2.04 Billion CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | 0.0% |
| 2007 | - CNY | 0.0% |
| 2006 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - CNY | 0.0% |
| 2024 Q1 | - CNY | 0.0% |
| 2023 Q4 | 16.67 Million CNY | 0.0% |
| 2023 Q2 | 26.28 Million CNY | 0.0% |
| 2023 FY | 16.67 Million CNY | 23.57% |
| 2023 Q1 | 26.28 Million CNY | 94.86% |
| 2023 Q3 | 16.67 Million CNY | -36.59% |
| 2022 FY | 13.49 Million CNY | -97.72% |
| 2022 Q4 | 13.49 Million CNY | 0.0% |
| 2022 Q3 | 13.49 Million CNY | -27.12% |
| 2022 Q2 | 18.51 Million CNY | 0.0% |
| 2022 Q1 | 18.51 Million CNY | -96.87% |
| 2021 Q3 | 593.58 Million CNY | 0.65% |
| 2021 Q4 | 591.62 Million CNY | -0.33% |
| 2021 Q2 | 589.74 Million CNY | -1.12% |
| 2021 FY | 591.62 Million CNY | -0.21% |
| 2021 Q1 | 596.42 Million CNY | 0.6% |
| 2020 Q3 | 598.76 Million CNY | -7.25% |
| 2020 Q2 | 645.6 Million CNY | -1.23% |
| 2020 Q1 | 653.65 Million CNY | 6130.61% |
| 2020 Q4 | 592.88 Million CNY | -0.98% |
| 2020 FY | 592.88 Million CNY | 5551.33% |
| 2019 Q2 | 6.4 Million CNY | 0.0% |
| 2019 Q1 | 6.4 Million CNY | -99.56% |
| 2019 FY | 10.49 Million CNY | -99.27% |
| 2019 Q4 | 10.49 Million CNY | 0.0% |
| 2019 Q3 | 10.49 Million CNY | 63.82% |
| 2018 Q1 | 1.39 Billion CNY | -31.52% |
| 2018 Q2 | 1.39 Billion CNY | 0.0% |
| 2018 Q3 | 1.44 Billion CNY | 3.09% |
| 2018 Q4 | 1.44 Billion CNY | 0.0% |
| 2018 FY | 1.44 Billion CNY | -29.4% |
| 2017 Q1 | 1.04 Billion CNY | 0.0% |
| 2017 Q4 | 2.04 Billion CNY | 0.0% |
| 2017 Q3 | 2.04 Billion CNY | 94.58% |
| 2017 Q2 | 1.04 Billion CNY | 0.0% |
| 2017 FY | 2.04 Billion CNY | 0.0% |
| 2016 Q3 | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2015 Q3 | - CNY | 0.0% |
| 2015 Q2 | - CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2014 FY | - CNY | 0.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2009 Q4 | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2008 FY | - CNY | 0.0% |
| 2007 FY | - CNY | 0.0% |
| 2006 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -704.197% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 98.316% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 85.766% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 93.964% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 76.399% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 53.765% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -30.232% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 79.442% |
| SSY Group Limited | 1.94 Billion HKD | 99.144% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 61.938% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 97.185% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.9% |